In our study, they were identified as AD repurposing candidates thanks to the proximity of FGFR1 and FGFR2 drug modules to disease modules of oligodendrocytes, oligodendrocyte progenitor cells, microglia, and inhibitory neurons. This evidence concerns the gene FGFR1 and Alzheimer disease.